|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125496 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-27 15:39:05 |
|
注册时间: Date of Registration: |
2026-05-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
健忘镇痛慢诱导联合BIS用于超高龄患者全身麻醉的安全性和有效性:一项随机、对照研究 |
|
Public title: |
Safety and efficacy of amnestic analgesic slow induction combined with BIS monitoring for general anesthesia in extremely elderly patients: a randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
健忘镇痛慢诱导联合BIS用于超高龄患者全身麻醉的安全性和有效性:一项随机、对照研究 |
|
Scientific title: |
Safety and efficacy of amnestic analgesic slow induction combined with BIS monitoring for general anesthesia in extremely elderly patients: a randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨恒 |
研究负责人: |
杨恒 |
|
Applicant: |
Yang Heng |
Study leader: |
Yang Heng |
|
申请注册联系人电话: Applicant telephone: |
+86 17380104465 |
研究负责人电话:
Study leader's |
+86 551 82139210 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yangh999@yeah.net |
研究负责人电子邮件: Study leader's E-mail: |
yangh999@yeah.net |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国安徽省合肥市庐阳区淮河路390号 |
研究负责人通讯地址: |
中国安徽省合肥市庐阳区淮河路390号 |
|
Applicant address: |
390 Huaihe Road, Luyang District, Hefei, Anhui, China |
Study leader's address: |
390 Huaihe Road, Luyang District, Hefei, Anhui, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
合肥市第一人民医院 |
||
|
Applicant's institution: |
Hefei First People's Hospital |
||
|
研究负责人所在单位: |
合肥市第一人民医院 |
||
|
Affiliation of the Leader: |
Hefei First People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦研批第2022-KY-03号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
合肥市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Hefei First People's hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-01-08 00:00:00 | ||
|
伦理委员会联系人: |
叶芝 |
||
|
Contact Name of the ethic committee: |
Ye Zhi |
||
|
伦理委员会联系地址: |
中国安徽省合肥市庐阳区淮河路390号 |
||
|
Contact Address of the ethic committee: |
390 Huaihe Road, Luyang District, Hefei, Anhui, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 551 62183685 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hfyykyc@163.com |
|
研究实施负责(组长)单位: |
合肥市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hefei First People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国安徽省合肥市庐阳区淮河路390号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
390 Huaihe Road, Luyang District, Hefei, Anhui, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖北陈孝平科技发展基金会临床研究专项基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hubei Chen Xiaoping Science and Technology Development Foundation Clinical Research Fund |
||||||||||||||||||||||
|
研究疾病: |
无 |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在评价健忘镇痛慢诱导联合脑电双频指数(BIS)监测在超高龄患者全身麻醉中的安全性和有效性。通过将阿芬太尼复合右美托咪定的慢诱导方式(A组)与传统快诱导方式(B组)对比,观察其对围术期血流动力学稳定性、术后恢复质量、不良反应及麻醉药用量的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to evaluate the safety and efficacy of a slow induction technique using amnesic analgesia combined with bispectral index (BIS) monitoring for general anesthesia in super-elderly patients. By comparing a slow induction method using alfentanil combined with dexmedetomidine (Group A) to a conventional rapid induction method (Group B), the study observes their effects on perioperative hemodynamic stability, postoperative recovery quality, adverse reactions, and anesthetic dosage. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)拟行下肢骨科手术的老年患者,包括胫腓骨骨折、髋部骨折(股骨颈骨 折、股骨粗隆间骨折)等; (2)预计手术时间 1~2 小时 (3)美国麻醉医师学会(ASA)身体状况 III-Ⅳ级; (4)年龄 75-99 岁,无性别限制; (5)签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Elderly patients scheduled for lower limb orthopedic surgery, including tibia and fibula fractures and hip fractures (femoral neck fractures, intertrochanteric femoral fractures); (2) Estimated surgery time: 1–2 hours; (3) American Society of Anesthesiologists (ASA) Physical Status III–IV; (4) Age 75–99 years, any gender; (5)Sign a written informed consent form; |
||||||||||||||||||||||
|
排除标准: |
(1)患者拒绝; (2)身体质量指数(BMI>30 kg/m^2或< 18kg/m^2); (3)严重心肺功能不全(LVEF<40%、PaO?<60 mmHg)、未控制的高血压(SBP>180 mmHg); (4)对相关麻醉药物过敏; (5)有精神、神经系统疾病或语言障碍,无法沟通配合治疗; (6)严重肝肾功能不全; (7)长期服用镇静镇痛药物。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1)Patient refusal; (2) Body mass index (BMI) > 30 kg/m^2 or < 18 kg/m^2; (3) Severe cardiopulmonary insufficiency (LVEF < 40%, PaO? < 60 mmHg) or uncontrolled hypertension (SBP > 180 mmHg); (4) Allergy to relevant anesthetic agents; (5) Presence of psychiatric or neurological disorders, or language barriers, preventing communication and cooperation with treatment; (6) Severe hepatic or renal insufficiency; (7) Long-term use of sedative or analgesic medications. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2025-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-01-03 00:00:00 至 To 2025-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机化分组方法:本次试验采用随机入组的方式进行临床研究,从而减少抽样误差所导致的试验偏倚,由一名独立于本临床试验的统计师完成随机分配表,随机分配表由SAS9.4或以上版本程序自动产生。对受试者进行随机化,研究组与对照组的比例1:1。研究者在核实入选/排除标准后,采取中央随机的方式,将受试者随机分配到相应编号的治疗组。整个试验过程中,治疗研究者不得对产生的随机数及受试者分配到的组别进行修改 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization and Group Assignment Method: This clinical trial will use random enrollment to reduce trial bias caused by sampling error. A statistician independent of this clinical trial will generate the randomization schedule. The randomization schedule will be automatically generated using SAS version 9.4 or later. Subjects will be randomized to the investigational group and the control group at a 1:1 ratio. After verifying the inclusion/exclusion criteria, investigators will use a central randomization method to randomly assign subjects to the correspondingly numbered treatment group. Throughout the trial, the treating investigators are not permitted to alter the generated random numbers or the group assignments of the subjects. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blind |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
根据试验进展,预计2026年1月以后,使用ResMan(http://www.medresman.org.cn/)共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Based on the progress of the trial, the raw data is expected to be shared via ResMan (http://www.medresman.org.cn/) after January 2026. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Report Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |